PCM
LCTX icon

Price Capital Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Price Capital Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-328,202
Closed -$430K – 50
2019
Q1 		$430K Buy
+328,202
New +$408K 0.12% 20

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Price Capital Management's LCTX Position: Q2 2019 in Review

Price Capital Management sold out of Lineage Cell Therapeutics (LCTX) in Q2 2019, closing a stake of 328,202 shares — an estimated $430K sold.

Price Capital Management first reported a position in LCTX in Q1 2019 and held it in 1 quarter. The position peaked at $430K in Q1 2019. 107 funds tracked by Wall St. Rank hold LCTX as of Q2 2019.

  • Price Capital Management reported no remaining Lineage Cell Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Price Capital Management sold 328,202 Lineage Cell Therapeutics shares in Q2 2019, an estimated $430K.
  • Price Capital Management first reported a position in Lineage Cell Therapeutics in Q1 2019 and held it in 1 quarter.
  • Price Capital Management's Lineage Cell Therapeutics position peaked at $430K in Q1 2019.
  • 107 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2019.

Based on Price Capital Management's 13F filing for Q2 2019, filed 5 Aug 2019.